To include your compound in the COVID-19 Resource Center, submit it here.

Genentech reports MetMAb data in NSCLC

Genentech Inc. plans to move MetMAb into Phase III testing this year for non-small cell lung cancer after Phase II data showed

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE